home / stock / amrn / amrn quote
Last: | $0.7848 |
---|---|
Change Percent: | 0.23% |
Open: | $0.7881 |
Close: | $0.7848 |
High: | $0.8 |
Low: | $0.7611 |
Volume: | 840,545 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.7848 | $0.7881 | $0.7848 | $0.8 | $0.7611 | 840,545 | 07-19-2024 |
$0.7899 | $0.79 | $0.7899 | $0.8042 | $0.7851 | 1,486,030 | 07-18-2024 |
$0.78 | $0.7755 | $0.78 | $0.8 | $0.76 | 754,981 | 07-17-2024 |
$0.7901 | $0.769 | $0.7901 | $0.8 | $0.7557 | 1,658,090 | 07-16-2024 |
$0.751 | $0.775 | $0.751 | $0.7755 | $0.7324 | 935,545 | 07-15-2024 |
$0.7807 | $0.74 | $0.7807 | $0.8 | $0.74 | 1,198,563 | 07-12-2024 |
$0.7458 | $0.76 | $0.7458 | $0.78 | $0.74 | 1,010,010 | 07-11-2024 |
$0.7585 | $0.6915 | $0.7585 | $0.7595 | $0.6915 | 1,632,500 | 07-10-2024 |
$0.7 | $0.736 | $0.7 | $0.7493 | $0.6892 | 1,544,331 | 07-09-2024 |
$0.7396 | $0.75 | $0.7396 | $0.7771 | $0.7113 | 1,887,925 | 07-08-2024 |
$0.7365 | $0.7 | $0.7365 | $0.739 | $0.6864 | 1,969,608 | 07-05-2024 |
$0.6864 | $0.71 | $0.6864 | $0.719 | $0.6814 | 721,053 | 07-04-2024 |
$0.6864 | $0.71 | $0.6864 | $0.719 | $0.6814 | 721,053 | 07-03-2024 |
$0.705 | $0.69 | $0.705 | $0.706 | $0.684 | 950,879 | 07-02-2024 |
$0.686 | $0.7 | $0.686 | $0.7074 | $0.686 | 707,634 | 07-01-2024 |
$0.688 | $0.7009 | $0.688 | $0.7149 | $0.6859 | 1,398,824 | 06-28-2024 |
$0.7009 | $0.7 | $0.7009 | $0.7238 | $0.696101 | 800,148 | 06-27-2024 |
$0.6982 | $0.73 | $0.6982 | $0.75 | $0.691 | 981,004 | 06-26-2024 |
$0.7283 | $0.6877 | $0.7283 | $0.7812 | $0.685 | 2,487,243 | 06-25-2024 |
$0.709 | $0.6981 | $0.709 | $0.7425 | $0.6805 | 1,489,585 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...